References
- Smith T J, Hillner B E, Desch C E. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. JNCI 1993; 85(18)1460–1474
- Schulman K A, Yabroff R K. Measuring the cost-effectiveness of cancer care. Oncology 1995; 9: 523–538
- Jaakimainen I, Goodwin P I, Pater J, Warde P, Murray N, Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8: 1301–1309
- Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized, controlled clinical trial. N Engl J Med 1988; 319: 902–907
- Kennedy B J. Excessive test costs in clinical research protocols. J Cancer Ed 1991; 6: 93–97
- Eisenberg J M, Glick H, Koffer H. Pharmacoeconomics: Economic evaluation of pharmaceuticals. Pharmacoepidemiology, B Strom. Churchill Livingstone, New York 1989
- Welch H G, Larson E B. Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989; 321: 807–812
- Ray W A, Griffin M R, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993; 329: 2029–2032
- Gulati S C, Bennett C L. Granulocyte-macrophage colony stimulating factor as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116: 177–182
- Welch H G. Valuing clinical strategies early in their development. Ann Intern Med 1992; 116: 263–264
- Drummond M F, Davies L. Economic analysis alongside clinical trials: Revisiting the methodologies issues. Int J Tech Assess Health Care 1991; 7: 561–563
- Haan G HG, Rutten F FH. Economic appraisal, health service planning, and budgetary management for the health technologies. Economic Appraisal of Health Technology in the European Community, M F Drummond. Oxford University Press, OxfordUK 1987; 135–146
- Cancer and Leukemia Group B. Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study. Protocol CALGB-9334 1994
- Eastern Cooperative Oncology Group. A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Colectomy Versus Open Colectomy for Colon Cancer. 1995, Protocol ECOG-E7293
- Children's Cancer Group. A Study of Minimally Invasive Surgery of the Chest in Children with Cancer. 1995, Protocol CCG-S942
- Pediatric Oncology Group. Assessment of the Role of Minimal Access Surgery in the Treatment of Childhood Cancer: Intergroup Laparoscopy Protocol. 1995, Protocol POG-9485
- Buxton M J. National Wilms' Tumor Study: Economic perspective. Monogr Natl Cancer Inst 1995; 19: 27–29
- Green D M, Breslow N E, Evans I, Moksness J, Finklestein J Z, Evans A E, D'Angio G J. Relationship between dose schedule and charges for treatment on National Wilms' Tumor Study-4. A report from the National Wilms' Tumor Study Group. Monogr Natl Cancer Inst 1995; 19: 21–25
- Bennett C L, Armitage J L, Lesage S, Gulati S, Armitage J O, Gorin C. Economic analyses of clinical trials in cancer: Are they helpful to policy makers?. Stem Cells 1994; 12: 424–429
- Bennett C L, Smith T J, George S L, Hillner B E, Fleishman S, Neill H B. Free-riding and the prisoner's dilemma: Problems in funding economic analyses of phase HI cancer clinical trials. J Clin Oncol 1995; 13: 2457–2463
- Bennett C L, Armitage J L, Buchner D, Gulati S. Economic analysis in phase III clinical trials. Cancer Invest 1994; 12: 336–342
- Drummond M F, Davies L. Economic analysis alongside clinical trials: Revisiting the methodologies issues. Int J Tech Assess Health Care 1991; 7: 561–563
- Drummond M F, Stoddart G L. (9). Economic analysis and clinical trial. Controlled Clin Trials 1984; 5: 115–128
- Bennett C L, Armitage J L, Buchner D, Gulati S. Economic analysis in phase III clinical cancer trials. Cancer Invest 1994; 12: 336–342
- Finkler S A. The distinction between cost and charges. Ann Intern Med 1982; 96: 102–109
- Bennett C L, George S L, Vose J M, et al. Granulocyte macrophage colony stimulating factor (GM-CSF) as adjunct therapy in relapsed lymphoid malignancy: Economic analyses of phase III clinical trials. Stem Cells 1995; 13: 414–420
- Hillman A L, Eisenberg J M, Pauly M V, Bloome B S, Glick K, Kinosian B, Schwartz J S. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362–1365